← Compound index
COMPOUND RECORD / OVAGEN

OvagenОваген

A short-peptide product described as containing glutamate, aspartate and leucine. Published product reports do not establish the order of these residues in the tested formulation.

Source linked

What the studies found

Comparison in people · 2011

Oral Ovagen in chronic hepatitis and after chemotherapy

Total bilirubin
21.5 vs 26.4 µmol/LOvagen plus usual care versus usual care. Shared baseline column 28.4 µmol/L.Ovagen result marked p < 0.05 versus baseline.
ALT
41.4 vs 44.3Ovagen plus usual care versus usual care. Shared baseline column 50.2. The table has a garbled unit label.Both post-treatment results marked p < 0.05 versus baseline.
IgM
2.1 vs 2.5 g/LOvagen plus usual care versus usual care. Shared baseline column 3.6 g/L.Both post-treatment results marked p < 0.05 versus baseline.

In the chronic-hepatitis table, bilirubin was 28.4 µmol/L before treatment, 21.5 after adjunctive Ovagen and 26.4 after usual care. ALT and IgM were marked lower than baseline in both groups.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

More reported outcomes
Cholesterol, AST, GGT and triglycerides
No significant change markedNo baseline-comparison asterisks on these rows.
Reported adverse effects
None reportedObservation was short. The report provides no structured adverse-event table.
Study notes · methods, sources and limitations

Participants or model 40 receiving adjunctive Ovagen (20 with persistent chronic hepatitis, 20 after chemotherapy) and 34 usual-care controls. The treated series was aged 38–67.

Design Adjunct-use comparison of 40 treated and 34 usual-care controls. The outcome tables below concern chronic hepatitis. The reported oral course was 15–20 days in the group description.

Important limitations

  • The report provides a shared baseline column and omits comparator subgroup sizes and allocation methods. Significance markers compare values with baseline. The 2011 compilation reproduces a 2005–2006 study and does not authenticate the protocol or establish that this product was the EDL sequence tested in kidney models.
  • The shared baseline and unspecified allocation prevent a reliable estimate of an effect attributable to Ovagen.

St. Petersburg Institute of Bioregulation and Gerontology Medical Center report (commercial reproduction) · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Ovagen

Research background

Ovagen is an oral peptide preparation studied alongside conventional care in chronic hepatitis and after chemotherapy. Experiments with synthetic EDL appear on the EDL profile.

Compound class
Peptide product / formulation research
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Institute-report reproduction covering 40 adjunct-treatment patients and 34 usual-care controls.

Study methods

Oral adjunct-treatment comparison, blood markers and liver ultrasound. Allocation unclear.

Independent replication

Independent replication not established in this collection

Source access

See source-specific abstracts, institute reports and explicit review scopes

Safety evidence

Systematic safety assessment incomplete

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Comparison in people · 2011

Oral Ovagen in chronic hepatitis and after chemotherapy

In the chronic-hepatitis table, bilirubin was 28.4 µmol/L before treatment, 21.5 after adjunctive Ovagen and 26.4 after usual care. ALT and IgM were marked lower than baseline in both groups.

Study notes and original source
2011Human comparative studyFull text available

Oral Ovagen in chronic hepatitis and after chemotherapy

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Named oral Ovagen product. The report lists glutamic acid, aspartic acid and leucine, with no sequence or batch characterization. · Institute report — commercial reproduction

A. A. Veretenko, O. Yu. Raigorodskii · St. Petersburg Institute of Bioregulation and Gerontology Medical Center report (commercial reproduction)

In the chronic-hepatitis table, bilirubin was 28.4 µmol/L before treatment, 21.5 after adjunctive Ovagen and 26.4 after usual care. ALT and IgM were marked lower than baseline in both groups.

Results and tables

Reported findings and study design

Adjunct-use comparison of 40 treated and 34 usual-care controls. The outcome tables below concern chronic hepatitis. The reported oral course was 15–20 days in the group description.

Population or model 40 receiving adjunctive Ovagen (20 with persistent chronic hepatitis, 20 after chemotherapy) and 34 usual-care controls. The treated series was aged 38–67.

Dose, route and schedule

The group methods describe two 0.100 mg capsules twice daily before meals for 15–20 days, alongside usual care. The introduction gives a broader tablet schedule of one to two twice daily for 10–20 days.

Protocol source ↗ · Russian commercial reproduction of the 2011 institute report, methods and Tables 1–3

Results · Russian commercial reproduction of the 2011 institute report, methods and Tables 1–3
MeasureResultComparison, timing and statistics
Total bilirubin21.5 vs 26.4 µmol/LOvagen plus usual care versus usual care. Shared baseline column 28.4 µmol/L. · Ovagen result marked p < 0.05 versus baseline.
ALT41.4 vs 44.3Ovagen plus usual care versus usual care. Shared baseline column 50.2. The table has a garbled unit label. · Both post-treatment results marked p < 0.05 versus baseline.
IgM2.1 vs 2.5 g/LOvagen plus usual care versus usual care. Shared baseline column 3.6 g/L. · Both post-treatment results marked p < 0.05 versus baseline.
Cholesterol, AST, GGT and triglyceridesNo significant change markedNo baseline-comparison asterisks on these rows.
Reported adverse effectsNone reportedObservation was short. The report provides no structured adverse-event table.
Tables 2–3 · selected chronic-hepatitis measurements
Tables 2–3 · selected chronic-hepatitis measurements
MeasureBaseline columnUsual careUsual care + Ovagen
Bilirubin (µmol/L)28.4 ± 0.526.4 ± 1.121.5 ± 0.7*
ALT (unit unclear)50.2 ± 3.244.3 ± 3.1*41.4 ± 2.8*
AST (unit unclear)38.6 ± 2.140.2 ± 2.236.1 ± 2.5
IgM (g/L)3.6 ± 0.032.5 ± 0.08*2.1 ± 0.03*
IgG (g/L)14.0 ± 1.214.2 ± 1.014.1 ± 1.1

Asterisks are from the source and indicate p < 0.05 versus the pretreatment value. The type of ± term is unspecified.

The shared baseline and unspecified allocation prevent a reliable estimate of an effect attributable to Ovagen.

Source for these results ↗ · Reviewed 2026-11-13

Population / setting
40 receiving adjunctive Ovagen (20 with persistent chronic hepatitis, 20 after chemotherapy) and 34 usual-care controls. The treated series was aged 38–67.
Source reviewed
Russian commercial reproduction of the 2011 institute report, methods and Tables 1–3
Study limitations
  • The report provides a shared baseline column and omits comparator subgroup sizes and allocation methods. Significance markers compare values with baseline.
  • The 2011 compilation reproduces a 2005–2006 study and does not authenticate the protocol or establish that this product was the EDL sequence tested in kidney models.

Reviewed 2026-11-13.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗